重组戊型肝炎疫苗（大肠埃希菌） | China Drugs ListRecombinant hepatitis E vaccine (Escherichia coli) | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 商品名
- 益可宁Hecolin
- 企业
- 厦门万泰沧海；厦门大学研发Xiamen Innovax Biotech; developed with Xiamen University
- 药品类型
- 疫苗Vaccine
- 治疗领域
- 预防与诊断Prevention & diagnosis
- 公开来源记录的适应症
- 用于16岁及以上易感人群，接种后可刺激机体产生抗戊型肝炎病毒的免疫力，用于预防戊型肝炎。说明书推荐的重点高风险人群包括畜牧养殖者、餐饮业人员、学生或部队官兵、育龄期妇女和疫区旅行者等。For susceptible individuals aged 16 years or older. Vaccination stimulates immunity against hepatitis E virus to prevent hepatitis E. Priority high-risk groups recommended in the prescribing information include livestock workers, food-service workers, students or military personnel, women of childbearing age, and travelers to endemic areas.
- 适应症来源与口径
- 来源日期： 2025-10-21, 2026-06-11. 生产商面向中国大陆的药品说明书。Source date(s): 2025-10-21, 2026-06-11. Manufacturer prescribing information for Mainland China.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.